Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This lone action constitutes the entire active prosecution workload for the university at the USPTO. The focus on 1 pending office action suggests that the institution is currently prioritizing a specific technical development within its broader research and development efforts.
The examination of this application is being handled by 1 distinct examiner, HABTE, KAHSAY. As the only official assigned to the portfolio, HABTE, KAHSAY is also the busiest examiner with 1 pending office action under his review. This prosecution is taking place within 1 distinct art unit, which further emphasizes the concentrated nature of the university's current patent activities in the Biotechnology & Pharmaceuticals sector.
For a practitioner, the presence of 1 distinct examiner and 1 distinct art unit for the 1 pending office action simplifies the interaction with the USPTO. There is no requirement to manage different examiner styles or art unit interpretations, as all activity is localized. This structure benefits from a direct line of communication with HABTE, KAHSAY, ensuring a consistent prosecution path for the 1 pending office action without the complexity of a distributed portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HABTE, KAHSAY | 1 | 84.9% | +7.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18554092 | DICHALCOGENIDE PRODRUGS | HABTE, KAHSAY | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18554092 | DICHALCOGENIDE PRODRUGS | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | — | Pending | Oct 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kahsay Habte has the most, with 1 of LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.